[Treatment and follow-up of superficial bladder cancer].
Raitanen
Mika
M
mika.raitanen@epshp.fi
D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D002278:Carcinoma in Situ / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D015653:Cystectomy; D006801:Humans; D009364:Neoplasm Recurrence, Local; D012307:Risk Factors; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents; D001500:BCG Vaccine